XML 37 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Debt - Long-Term Debt from Royalty-Bearing Instrument-December 2012 Financing - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 06, 2012
Nov. 30, 2019
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Debt Disclosure [Line Items]            
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount     $ 59,550,000 $ 59,550,000   $ 79,710,000
Interest expense, non-cash       1,282,000 $ 1,687,000  
CPPIB            
Debt Disclosure [Line Items]            
Maximum repayment of future revenue and receivables     63,600,000 63,600,000    
Repayment under agreement     10,000,000.0 $ 25,000,000.0    
CPPIB | Scenario Forecast            
Debt Disclosure [Line Items]            
Repayment under agreement   $ 11,200,000        
CPPIB | Vascepa            
Debt Disclosure [Line Items]            
Debt and future repayments percentage of net revenues       10.00%    
BioPharma Debt            
Debt Disclosure [Line Items]            
Amount received at the closing of the agreement $ 100,000,000.0          
Maximum repayment of future revenue and receivables 150,000,000.0          
Royalty-Bearing Debt            
Debt Disclosure [Line Items]            
Fair value of embedded derivative liability $ 14,600,000          
Gain (loss) on change in fair value of derivative liabilities       $ 0 0  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount     $ 59,500,000 59,500,000   $ 79,700,000
Royalty-Bearing Debt | Cash            
Debt Disclosure [Line Items]            
Interest expense, contractual coupon interest       3,400,000 4,300,000  
Royalty-Bearing Debt | Non Cash            
Debt Disclosure [Line Items]            
Interest expense, non-cash       $ 1,300,000 $ 1,500,000